중견 제약 시장 보고서(2026년)

Mid-sized pharmaceutical companies are defined as organizations with annual revenues ranging between $1 billion and $10 billion. These companies typically focus on areas such as drug development, niche market targeting, regional expansion, strategic partnerships, generic drug manufacturing, and contract manufacturing services.

The main approaches to drug development in mid-sized pharmaceutical companies include in-house development and outsourced development. In-house development refers to activities carried out internally by a company's own employees and departments rather than being delegated to external contractors. Within mid-sized pharmaceutical companies, in-house operations commonly include functions such as research and development, manufacturing, quality control, regulatory affairs, sales and marketing, and other core business activities. These companies operate both prescription and over-the-counter facilities that manufacture and sell medicines in forms such as tablets, capsules, injectables, sprays, and others, which are used to treat conditions including cardiovascular diseases, pain management, diabetes, cancer, and other disorders.

Tariffs have impacted the mid-size pharmaceuticals market by increasing the cost of imported raw materials, active pharmaceutical ingredients (APIs), and specialized manufacturing equipment. This has particularly affected contract manufacturing and generic drug production segments, especially in regions like Asia-Pacific and Europe that are major suppliers. While the tariffs have increased operational costs and slowed production timelines, they have also encouraged local sourcing, boosted domestic manufacturing investments, and accelerated innovation in cost-efficient drug development processes.

The mid-size pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides mid-size pharmaceuticals market statistics, including mid-size pharmaceuticals industry global market size, regional shares, competitors with a mid-size pharmaceuticals market share, detailed mid-size pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the mid-size pharmaceuticals industry. This mid-size pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mid-size pharmaceuticals market size has grown strongly in recent years. It will grow from $760.71 billion in 2025 to $808.69 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increased r&d investments, expansion into emerging markets, adoption of generic drug production, growth of regional partnerships, rising prevalence of chronic diseases.

The mid-size pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $1059.05 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to advancements in personalized medicine, increased outsourcing of cros & cmos, adoption of ai-driven drug discovery, expansion of digital health platforms, growth in specialty pharmaceuticals. Major trends in the forecast period include niche drug development focus, regional market expansion, strategic partnerships & collaborations, generic drug manufacturing growth, contract manufacturing optimization.

The increasing prevalence of chronic diseases is expected to drive the growth of the mid-size pharmaceuticals market in the coming years. Chronic diseases, also referred to as non-communicable diseases, are long-term medical conditions that require continuous management and treatment, resulting in sustained demand for pharmaceutical products. Techniques such as mass spectrometry are widely used to identify, quantify, and analyze biomarkers and metabolites associated with chronic diseases, supporting drug development and disease management. As the burden of chronic illnesses continues to rise, it contributes directly to the expansion of the mid-size pharmaceuticals market. For instance, in June 2024, according to the National Health Service, 3,615,330 individuals registered with a general practitioner in the UK were diagnosed with non-diabetic hyperglycemia, or pre-diabetes, in 2023, representing an 18% increase compared to 3,065,825 cases in 2022. Therefore, the growing prevalence of chronic diseases is fueling the growth of the mid-size pharmaceuticals market.

Companies operating in the mid-size pharmaceuticals sector are increasingly concentrating on product development and new launches, including precision medicine platforms, to maintain and strengthen their market positions. A precision medicine platform is an advanced system designed to customize medical treatments based on individual patient characteristics, such as genetic profiles. For example, in February 2023, C4X Discovery Holdings PLC introduced its precision medicine platform, PatientSeek. The platform is intended to identify patient subgroups most likely to benefit from specific therapies based on genetic insights. The launch followed successful validation in patient stratification, where responsive patient groups were identified through retrospective analysis of a Phase 3 clinical trial in Parkinson's disease, highlighting the role of genetics in optimizing targeted treatment strategies.

In March 2023, Sun Pharmaceutical Industries Limited acquired Concert Pharmaceuticals Inc. for $576 million. Through this acquisition, Sun Pharmaceutical Industries gained full ownership of Concert's outstanding shares and added deuruxolitinib, a novel deuterated oral JAK1/2 inhibitor under development for the treatment of moderate to severe alopecia areata in adults, to its pipeline. Concert Pharmaceuticals Inc. is a US-based late-stage clinical mid-sized biopharmaceutical company focused on developing innovative medicines with distinct therapeutic profiles.

Major companies operating in the mid-size pharmaceuticals market are Baxter International Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Alexion Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Les Laboratoires Servier S.A., Perrigo Co Plc, Aurobindo Pharma Limited., Cipla Limited, Hikma Pharmaceuticals, Endo International plc, Taisho Pharmaceutical Holdings Co. Ltd., BioMarin Pharmaceutical Inc., Mallinckrodt Plc, Exelixis Inc., Mylan Pharmaceuticals Inc., Neurocrine Biosciences Inc., Kyowa Kirin Co. Ltd., Emergent BioSolutions Inc.

North America was the largest region in the mid-size pharmaceutical market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mid-size pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mid-size pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mid-sized pharmaceuticals market consists of revenues earned by entities providing pharmaceutical services such as drug development, research activities, generic drug manufacturing, and contract manufacturing. The market value includes the value of related goods sold by the service provider or included within the service offering. The mid-sized pharmaceuticals market consists of the sales of goods such as prescription drugs, over-the-counter medications, generic drugs, and other pharmaceutical products targeting specific therapeutic areas or niche markets. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mid-Size Pharmaceuticals Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses mid-size pharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mid-size pharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mid-size pharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Development Type: In-House; Outsource
• 2) By Type: Prescription; Over The Counter
• 3) By Formulation: Tablets; Capsules; Injectables; Sprays; Other Formulations
• 4) By Application: Cardiovascular Diseases; Pain Management; Diabetes; Cancer; Other Conditions
• Subsegments:
• 1) By In-House: Research And Development (R&D) Departments; Clinical Trials Management
• 2) By Outsource: Contract Research Organizations (CROs); Contract Manufacturing Organizations (CMOs)
• Companies Mentioned: Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Otsuka Pharmaceutical Co Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Co. Ltd.; Alexion Pharmaceuticals Inc.; UCB S.A.; Sun Pharmaceutical Industries Ltd.; Eisai Co. Ltd.; Les Laboratoires Servier S.A.; Perrigo Co Plc; Aurobindo Pharma Limited.; Cipla Limited; Hikma Pharmaceuticals; Endo International plc; Taisho Pharmaceutical Holdings Co. Ltd.; BioMarin Pharmaceutical Inc.; Mallinckrodt Plc; Exelixis Inc.; Mylan Pharmaceuticals Inc.; Neurocrine Biosciences Inc.; Kyowa Kirin Co. Ltd.; Emergent BioSolutions Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Mid-Size Pharmaceuticals Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Mid-Size Pharmaceuticals Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Mid-Size Pharmaceuticals Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Mid-Size Pharmaceuticals Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Niche Drug Development Focus
  • 4.2.2 Regional Market Expansion
  • 4.2.3 Strategic Partnerships & Collaborations
  • 4.2.4 Generic Drug Manufacturing Growth
  • 4.2.5 Contract Manufacturing Optimization

5. Mid-Size Pharmaceuticals Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Pharmaceutical Wholesalers
• 5.4 Retail Pharmacies
• 5.5 Research Laboratories

6. Mid-Size Pharmaceuticals Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Mid-Size Pharmaceuticals Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Mid-Size Pharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Mid-Size Pharmaceuticals Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Mid-Size Pharmaceuticals Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Mid-Size Pharmaceuticals Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Mid-Size Pharmaceuticals Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Mid-Size Pharmaceuticals Market Segmentation

• 9.1. Global Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• In-House, Outsource
• 9.2. Global Mid-Size Pharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prescription, Over The Counter
• 9.3. Global Mid-Size Pharmaceuticals Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tablets, Capsules, Injectables, Sprays, Other Formulations
• 9.4. Global Mid-Size Pharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cardiovascular Diseases, Pain Management, Diabetes, Cancer, Other Conditions
• 9.5. Global Mid-Size Pharmaceuticals Market, Sub-Segmentation Of In-House, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Research And Development (R&D) Departments, Clinical Trials Management
• 9.6. Global Mid-Size Pharmaceuticals Market, Sub-Segmentation Of Outsource, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs)

10. Mid-Size Pharmaceuticals Market Regional And Country Analysis

• 10.1. Global Mid-Size Pharmaceuticals Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Mid-Size Pharmaceuticals Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Mid-Size Pharmaceuticals Market

• 11.1. Asia-Pacific Mid-Size Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Mid-Size Pharmaceuticals Market

• 12.1. China Mid-Size Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Mid-Size Pharmaceuticals Market

• 13.1. India Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Mid-Size Pharmaceuticals Market

• 14.1. Japan Mid-Size Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Mid-Size Pharmaceuticals Market

• 15.1. Australia Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Mid-Size Pharmaceuticals Market

• 16.1. Indonesia Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Mid-Size Pharmaceuticals Market

• 17.1. South Korea Mid-Size Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Mid-Size Pharmaceuticals Market

• 18.1. Taiwan Mid-Size Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Mid-Size Pharmaceuticals Market

• 19.1. South East Asia Mid-Size Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Mid-Size Pharmaceuticals Market

• 20.1. Western Europe Mid-Size Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Mid-Size Pharmaceuticals Market

• 21.1. UK Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Mid-Size Pharmaceuticals Market

• 22.1. Germany Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Mid-Size Pharmaceuticals Market

• 23.1. France Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Mid-Size Pharmaceuticals Market

• 24.1. Italy Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Mid-Size Pharmaceuticals Market

• 25.1. Spain Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Mid-Size Pharmaceuticals Market

• 26.1. Eastern Europe Mid-Size Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Mid-Size Pharmaceuticals Market

• 27.1. Russia Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Mid-Size Pharmaceuticals Market

• 28.1. North America Mid-Size Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Mid-Size Pharmaceuticals Market

• 29.1. USA Mid-Size Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Mid-Size Pharmaceuticals Market

• 30.1. Canada Mid-Size Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Mid-Size Pharmaceuticals Market

• 31.1. South America Mid-Size Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Mid-Size Pharmaceuticals Market

• 32.1. Brazil Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Mid-Size Pharmaceuticals Market

• 33.1. Middle East Mid-Size Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Mid-Size Pharmaceuticals Market

• 34.1. Africa Mid-Size Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Mid-Size Pharmaceuticals Market, Segmentation By Drug Development Type, Segmentation By Type, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Mid-Size Pharmaceuticals Market Regulatory and Investment Landscape

36. Mid-Size Pharmaceuticals Market Competitive Landscape And Company Profiles

• 36.1. Mid-Size Pharmaceuticals Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Mid-Size Pharmaceuticals Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Mid-Size Pharmaceuticals Market Company Profiles
  • 36.3.1. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Otsuka Pharmaceutical Co Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Daiichi Sankyo Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Mid-Size Pharmaceuticals Market Other Major And Innovative Companies

• Alexion Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Les Laboratoires Servier S.A., Perrigo Co Plc, Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals, Endo International plc, Taisho Pharmaceutical Holdings Co. Ltd., BioMarin Pharmaceutical Inc., Mallinckrodt Plc, Exelixis Inc., Mylan Pharmaceuticals Inc.

38. Global Mid-Size Pharmaceuticals Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Mid-Size Pharmaceuticals Market

40. Mid-Size Pharmaceuticals Market High Potential Countries, Segments and Strategies

• 40.1 Mid-Size Pharmaceuticals Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Mid-Size Pharmaceuticals Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Mid-Size Pharmaceuticals Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer